Cyclooxygenase-2 is involved in HIV-1 Tat-induced inflammatory responses in the brain

NeuroMolecular Medicine

Volumn 8, Issue 3, 2006, Pages 337-351

  Flora, Govinder ^a   Pu, Hong ^a   Hennig, Bernhard ^b   Toborek, Michal ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

CNS; COX; HIV 1; HIV associated dementia; Inflammation; NF B; Tat

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTANOID; PYRROLIDINE DITHIOCARBAMATE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; ENCEPHALITIS; ENZYME INDUCTION; ENZYME LOCALIZATION; GENE OVEREXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFLAMMATION; MALE; MICROGLIA; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745248085     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:8:3:337     Document Type: Article

References (62)

1. Beg A. A., Finco T. S., Nantermet P. V., and Baldwin A. S. Jr. (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol. Cell. Biol. 13, 3301-3310.
2. Blanco A. M., Pascual M., Valles S. L., and Guerri C. (2004) Ethanol-induced iNOS and COX-2 expression in cultured astrocytes via NF-kappa B. Neuroreport 15, 681-685.
3. Bruce-Keller A. J., Barger S. W., Moss N. I., Pham J. T., Keller J. N., and Nath A. (2001) Pro-inflammatory and pro-oxidant properties of the HIV protein Tat in a microglial cell line: attenuation by 17 beta-estradiol. J. Neurochem. 78, 1315-1324.
4. Bruce-Keller A. J., Chauhan A., Dimayuga F. O., Gee J., Keller J. N., and Nath A. (2003) Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J. Neurosci. 23, 8417-8422.
5. Caughey G. E., Pouliot M., Cleland L. G., and James M. J. (1997) Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes. J. Immunol. 158, 351-358.
6. Chauhan A., Turchan J., Pocernich C. et al. (2003) Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 278, 13512-13519.
7. Corasaniti M. T., Bellizzi C., Russo R., Colica C., Amantea D., and Di Renzo G. (2003) Caspase-1 inhibitors abolish deleterious enhancement of COX-2 expression induced by HIV-1 gp120 in human neuroblastoma cells. Toxicol. Lett. 139, 213-219.
8. D'Aversa T. G., Yu K. O., and Berman J. W. (2004) Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J. Neurovirol. 10, 86-97.
9. Engblom D., Ek M., Saha S., Ericsson-Dahlstrand A., Jakobsson P. J., and Blomqvist A. (2002) Prostaglandins as inflammatory messengers across the blood-brain barrier. J. Mol. Med. 80, 5-15.
10. Ensoli B., Buonaguro L., Barillari G., et al. (1993) Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67, 277-287.
11. Feuerstein G. Z., Wang X., and Barone F. C. (1997) Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann. N. Y. Acad. Sci. 825, 179-193.
12. Flora G., Lee Y. W., Nath A., Hennig B., Maragos W., and Toborek M. (2003) Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 179, 60-70.
13. Futaki N., Yoshikawa K., Hamasaka Y., et al. (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 24, 105-110.
14. Griffin D. E., Wesselingh S. L., and McArthur J. C. (1994) Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann. Neurol. 35, 592-597.
15. Hara K., Kong D. L., Sharp F. R., and Weinstein P. R. (1998) Effect of selective inhibition of cyclooxygenase 2 on temporary focal cerebral ischemia in rats. Neurosci. Lett. 256, 53-56.
16. Haughey N. J., and Mattson M. P. (2002) Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J. Acquir. Immune Defic. Syndr. 31(Suppl 2), S55-S61.
17. Hoozemans J. J., Veerhuis R., Janssen I., van Elk E. J., Rozemuller A. J., and Eikelenboom P. (2002) The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res. 951, 218-226.
18. Hudson L., Liu J., Nath A., et al. (2000) Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J. Neurovirol. 6, 145-155.
19. Huigen M. C., Kamp W., and Nottet H. S. (2004) Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur. J. Clin. Invest. 34, 57-66.
20. Hurley S. D., Olschowka J. A., and O'Banion M. K. (2002) Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J. Neurotrauma 19, 1-15.
21. Israel N. and Gougerot-Pocidalo M. A. (1997) Oxidative stress in human immunodeficiency virus infection. Cell. Mol. Life Sci. 53, 864-870.
22. Khan N. A., Di Cello F., Nath A., and Kim K. S. (2003) Human immunodeficiency virus type 1 tat-mediated cytotoxicity of human brain microvascular endothelial cells. J. Neurovirol. 9, 584-593.
23. Khurdayan V. K., Buch S., El-Hage N., et al. (2004) Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur. J. Neurosci. 19, 3171-3182.
24. Kim T. A., Avraham H. K., Koh Y. H., Jiang S., Park I. W., and Avraham S. (2003) HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J. Immunol. 170, 2629-2637.
25. Kruman I. I., Nath A., and Mattson M. P. (1998) HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp. Neurol. 154, 276-288.
26. Kruman I. I., Nath A., Maragos W. F., et al. (1999) Evidence that Par-4 participates in the pathogenesis of HIV encephalitis. Am. J. Pathol. 155, 39-46.
27. Kyrkanides S., Moore A. H., Olschowka J. A., et al. (2002) Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury. Brain Res. Mol. Brain Res. 104, 159-169.
28. Liu Q. N., Reddy S., Sayre J. W., Pop V., Graves M. C., and Fiala M. (2001) Essential role of HIV type 1-infected and cyclooxygenase 2-activated macrophages and T cells in HIV type 1 myocarditis. AIDS Res. Hum. Retroviruses 17, 1423-1433.
29. Liu X., Jana M., Dasgupta S., et al. (2002) Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J. Biol. Chem. 277, 39,312-39,319.
30. Ma M. and Nath A. (1997) Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J. Virol. 71, 2495-2499.
31. Madrigal J. L., Garcia-Bueno B., Moro M. A., Lizasoain I., Lorenzo P., and Leza J. C. (2003) Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur. J. Neurosci. 18, 1701-1705.
32. Madrigal J. L., Caso J. R., de Cristobal J., et al. (2003) Effect of subacute and chronic immobilisation stress on the outcome of permanent focal cerebral ischaemia in rats. Brain Res. 979, 137-145.
33. Magnuson D. S., Knudsen B. E., Geiger J. D., Brownstone R. M., and Nath A. (1995) Human immunodeficiency virus type 1 tat activates non-N-methyl-D- aspartate excitatory amino acid receptors and causes neurotoxicity. Ann. Neurol. 37, 373-380.
34. Masferrer J. L., Zweifel B. S., Manning P. T., et al. (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 91, 3228-3232.
35. Matzen K., Dirkx A. E., oude Egbrink M. G., et al. (2004) HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res. 104, 145-155.
36. Minghetti L., Visentin S., Patrizio M., Franchini L., Ajmone-Cat M. A., and Levi G. (2004) Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem. Res. 29, 965-978.
37. Monaco C. and Paleolog E. (2004) Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc. Res. 61, 671-682.
38. Nabel G. and Baltimore D. (1987) An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326, 711-713.
39. Nath A., Conant K., Chen P., Scott C., and Major E. O. (1999) Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J. Biol. Chem. 274, 17,098-17,102.
40. Nath A., Psooy K., Martin C., et al. (1996) Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70, 1475-1480.
41. New D. R., Ma M., Epstein, L. G., Nath A., and Gelbard H. A. (1997) Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J. Neurovirol. 3, 168-173.
42. Nogawa S., Zhang F., Ross M. E., and Iadecola C. (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17, 2746-2755.
43. Nottet H. S. (1999) Interactions between macrophages arid brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood-brain barrier function. J. Neurovirol. 5, 659-669.
44. Pereira C. F., Boven L. A., Middel J., Verhoef J., and Nottet H. S. (2000) Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions. J. Leukoc. Biol. 68, 423-428.
45. Petito C. K., Roberts B., Cantando J. D., Rabinstein A., and Duncan R. (2001) Hippocampal injury and alterations in neuronal chemokine co-receptor expression in patients with AIDS. J. Neuropathol. Exp. Neurol. 60, 377-385.
46. Poligone B. and Baldwin A. S. (2001) Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J. Biol. Chem. 276, 38,658-38,664.
47. Pu H., Tian J., Flora G., et al. (2003) HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol. Cell. Neurosci. 24, 224-237.
48. Rose J. W., Hill K. E., Watt H. E., and Carlson N. G. (2004) Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J. Neuroimmunol. 149, 40-49.
49. Shor-Posner G. (2000) Cognitive function in HIV-1-infected drug users. J. Acquir. Immune. Defic. Syndr. 25(Suppl 1), S70-S73.
50. Sugimoto K. and Iadecola C. (2003) Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res. 960, 273-276.
51. Tanabe T. and Tohnai N. (2002) Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 68-69, 95-114.
52. Toborek M., Lee Y. W., Kaiser S., and Hennig B. (2002) Measurement of inflammatory properties of fatty acids in human endothelial cells. Methods Enzymol. 352, 198-219.
53. Toborek M., Lee Y. W., Pu H., et al. (2003) HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J. Neurochem. 84, 169-179.
54. Torres-Munoz J., Stockton P., Tacoronte N., Roberts B., Maronpot R. R., and Petito C. K. (2001) Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture microdissection. J. Neuropathol. Exp. Neurol. 60, 885-892.
55. Valle L. D., Croul S., Morgello S., Amini S., Rappaport J., and Khalili K. (2000) Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J. Neurovirol. 6, 221-228.
56. Vives E., Richard J. P., Rispal C., and Lebleu B. (2003) TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci. 4, 125-132.
57. Warner T. D. and Mitchell J. A. (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18, 790-804.
58. Woodman S. E., Benveniste E. N., Nath A., and Berman J. W. (1999) Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes. J. Neurovirol. 5, 678-684.
59. Wang T., Qin L., Liu B., et al. (2004) Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J. Neurochem. 88, 939-947.
60. Wu K. K. (2003) Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thromb. Res. 110, 273-276.
61. Wu R. F., Gu Y., Xu Y. C., Mitola S., Bussolino F., and Terada L. S. (2004) Human immunodeficiency virus type 1 Tat regulates endothelial cell actin cytoskeletal dynamics through PAK1 activation and oxidant production. J. Virol. 78, 779-789.
62. Zink W. E., Anderson E., Boyle J., et al. (2002) Impaired spatial cognition and synaptic potentiation in a marine model of human immunodeficiency virus type 1 encephalitis. J. Neurosci. 22, 2096-2105.